Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Renouncing your U.S. citizenship costs just $450. But...
Business & Finance

Renouncing your U.S. citizenship costs just $450. But there’s a world of hidden costs, too.

Renouncing your U.S. citizenship costs just $450. But there’s a world of hidden costs, too.
MarketWatch Wednesday 17 June 2026, 14:00 UTC By Edd and Cynthia Staton 1 min read
Key Points

Before cutting legal ties to the country, consider the expenses.

Before cutting legal ties to the country, consider the expenses.
U.S. (LOCATION)
Originally published by MarketWatch Read original →

Related Stories

Pick up these soon-to-be breakout stars while you ...

If it feels like this season has been brutal on the injury front, particularly among the game's most prominent players, you're not wrong. Seven of the first 11 players picked (on average) in ESPN leagues during the preseason have already spent time on the injured list, with every one of them either having spent or expected to spend longer than a minimum stint on the sidelines: Aaron Judge, No. 2 in ADP, likely out until at least mid-July Juan Soto, No. 3, 19 days Tarik Skubal, No. 6, 43 days...

ESPN just now

Mutares Is Said to Mull Sale or IPO of Portuguese Firm Efacec

Deals Mutares Is Said to Mull Sale or IPO of Portuguese Firm Efacec Mutares SE & Co. is exploring options for Portuguese engineering group Efacec, according to people familiar with the matter. The German investment firm is working with advisers including JPMorgan Chase & Co. on the options, which could include an initial public offering in Lisbon or a sale, said the people, who asked not to be identified discussing private information. The unit has attracted preliminary interest from...

Bloomberg Markets 11m ago

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

UniQure plans to seek FDA approval of its experimental gene therapy for Huntington's disease, the company said Wednesday, months after previous agency leaders criticized the evidence backing the application. UniQure said the FDA in a recent meeting communicated that a three-year analysis from a Phase 1/2 study would support an accelerated approval of UniQure's gene therapy for Huntington's, a rare hereditary disease that gradually destroys nerve cells in the brain. As a result of the...

CNBC 12m ago

Luigi Mangione to use psychiatric defence in health CEO murder trial, judge says

Brian Thompson was killed in December 2024 as he walked to a Manhattan hotel for UnitedHealth Group’s annual investor conference.

Euronews 13m ago